# NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required) (PAR-27-065)

**Plain-English Eligibility Score:** 80/100

| Field | Value |
|---|---|
| Opportunity number | PAR-27-065 |
| Title | NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required) |
| Agency | National Institutes of Health |
| Status | posted |
| Posted / open date | 2026-08-31 |
| Close date | 2029-03-09 |
| Award ceiling | n/a |
| Award floor | n/a |
| Estimated total funding | n/a |
| Funding category | Health |
| Eligible applicants | County governments; Independent school districts; Small businesses; Special district governments; Private institutions of higher education; City or township governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Native American tribal governments (Federally recognized); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; State governments; Native American tribal organizations (other than Federally recognized tribal governments) |
| Eligibility notes | Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no l |
| CFDA / Assistance listing | 93.853 |
| Summary | This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS and may include studies of small molecules, biologics, devices as well as surgical, behavioral, diet-based, or rehabilitation therapies. Studies addressing neurological diseases and care across the lifespan are highly encouraged. This notice invites both early- and middle-phase exploratory clinical trials as well as later phase confirmatory Phase 3 or comparative effectiveness clinical trials. |
| Agency contact | Exploratory_Efficacy_Trials@ninds.nih.gov |

## Why this score
- Small businesses are listed as eligible applicants.
- Nonprofits are listed as eligible applicants.
- 855 days until the deadline: enough time to prepare a strong application.

Source: Grants.gov (U.S. Department of Health and Human Services) (https://www.grants.gov/search-results-detail/360404). Last refreshed: 2026-11-04T18:11:59.874Z.
Data from Grants.gov. Always read the full notice of funding opportunity before applying. Informational only; not legal or grant-writing advice.